Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 10, 8, 2, 63, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 25 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Overview
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Companies Involved in Therapeutics Development
AbbVie Inc
Acticule Life Sciences Ltd
Acurx Pharmaceuticals Inc
AEON Medix Inc
AimMax Therapeutics Inc
AlphaMab Co Ltd
Amicrobe Inc
Amprologix Ltd
AnyGen Co Ltd
Aphios Corp
Aridis Pharmaceuticals Inc
Arietis Corp
Aurigene Discovery Technologies Ltd
Basilea Pharmaceutica Ltd
Bharat Biotech Ltd
Biomendics LLC
BioPlx Microbiomics Pvt Ltd
Bioseka UAB
Bioversys AG
Botanix Pharmaceuticals Ltd
Cantab Anti-infectives Ltd
Cellics Therapeutics Inc
Centivax Inc
Chengdu Olymvax Biopharmaceuticals Inc
Crestone Inc
CrystalGenomics Inc
CSA Biotechnologies LLC
Curza Global LLC
Daiichi Sankyo Co Ltd
Debiopharm International SA
DeNovaMed Inc
Destiny Pharma Plc
Eagle Pharmaceuticals Inc
Enesi Pharma Ltd
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Exbaq LLC
Global BioLife Inc Ltd
Helperby Therapeutics Group Ltd
Histogen Inc
Hsiri Therapeutics LLC
HyPharm GmbH
ImmunArtes LLC
Immupharma Plc
Inimmune Corp
Integrated BioTherapeutics Inc
ioGenetics Inc
Johnson & Johnson
KBP Biosciences Co Ltd
Lakewood-Amedex Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
Lysimmune BioScience
Lyticon LLC
Madam Therapeutics BV
Matrisys Bioscience Inc
Meiji Seika Pharma Co Ltd
MGB Biopharma Ltd
Microbiotix Inc
MicuRx Pharmaceuticals Inc
Naicons Srl
Neupharma Srl
Novabiotics Ltd
Novalex Therapeutics Inc
NovoBiotic Pharmaceuticals LLC
Olgram SAS
Opal Biosciences Ltd
Oppilotech Ltd
Oragenics Inc
Oryn Therapeutics
Oxford Drug Design Ltd
Peptineo
Pharma Holdings AS
Phico Therapeutics Ltd
Prokaryotics Inc
Prommune Inc
Q2 Pharma Ltd
QureTech Bio AB
Recce Pharmaceuticals Ltd
Sano Chemicals Inc
Scandion Oncology AS
SciBac Inc
Sentinella Pharmaceuticals Inc
Shanghai Shangyao Xinya Pharmaceutical Co Ltd
Shanghai Space Peptides Pharmaceutical Co Ltd
Sinsa Labs Inc
Skye Bioscience Inc
Sorrento Therapeutics Inc
Synspira Therapeutics Inc
TaeJoon Pharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
TAXIS Pharmaceuticals Inc
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Theravance Biopharma Inc
Trellis Bioscience Inc
Venomyx Inc
Viosera Therapeutics
Vitas Pharma Research Pvt Ltd
VLP Biotech Inc
Wockhardt Ltd
Yungjin Pharm Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd
Zydus Lifesciences Ltd
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profiles
(meropenem + piperacillin + tazobactam) – Drug Profile
(mupirocin calcium + neomycin sulfate + HT-61) – Drug Profile
ACH-702 – Drug Profile
ACX-375C – Drug Profile
ADEP-4 – Drug Profile
afabicin – Drug Profile
AGM-290 – Drug Profile
ALS-2 – Drug Profile
ALS-3 – Drug Profile
ALS-4 – Drug Profile
AM-0016 – Drug Profile
Anti-bacterial 1 – Drug Profile
APY-281 – Drug Profile
AU-1702014 – Drug Profile
B-2088 – Drug Profile
BDM-I – Drug Profile
berkeleylactone A – Drug Profile
Beta Lactam Antibiotics + BPEI – Drug Profile
BioPlx-01KS – Drug Profile
BioPlx-01WT – Drug Profile
BSK-003 – Drug Profile
BTX-1801 – Drug Profile
BV-200 – Drug Profile
CAL-02 – Drug Profile
cefilavancin – Drug Profile
ceftobiprole medocaril – Drug Profile
Cellular Immunotherapy for MRSA Infections – Drug Profile
CG-549 – Drug Profile
ClyO – Drug Profile
contezolid – Drug Profile
contezolid acefosamil – Drug Profile
CRS-0540 – Drug Profile
CSA-13 – Drug Profile
CTI-005 – Drug Profile
CTI-036 – Drug Profile
CYTOLYSIN – Drug Profile
CZ-25 – Drug Profile
CZ-52 – Drug Profile
dalbavancin – Drug Profile
darwinolide – Drug Profile
delpazolid – Drug Profile
diflunisal – Drug Profile
Drugs for Methicillin-Resistant Staphylococcus Aureus Infections – Drug Profile
emricasan – Drug Profile
EP-67 – Drug Profile
Epidermicin NI-01 – Drug Profile
EVQ-221 – Drug Profile
exeporfinium chloride – Drug Profile
F-12 – Drug Profile
F-19 – Drug Profile
firmocidin – Drug Profile
GmPcide-1 – Drug Profile
HT-01 – Drug Profile
HT-02 – Drug Profile
Humimycin A – Drug Profile
HY-004B8b – Drug Profile
HY-005B8a – Drug Profile
HY-133 – Drug Profile
IBN-1 – Drug Profile
infectious disease vaccine – Drug Profile
IOG-101 – Drug Profile
IPP-203101 – Drug Profile
KBP-7072 – Drug Profile
KKL-35 – Drug Profile
KN-043 – Drug Profile
KVH-147 – Drug Profile
LB-2 – Drug Profile
LCB-010699 – Drug Profile
levonadifloxacin – Drug Profile
LI-03 – Drug Profile
LTX-109 – Drug Profile
lysostaphin – Drug Profile
Marinus – Drug Profile
MGBBP-3 – Drug Profile
Monoclonal Antibodies for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profile
Mul-1867 – Drug Profile
MUT-001 – Drug Profile
NAI-107 – Drug Profile
NAI-603 – Drug Profile
NAIAPOL-2001 – Drug Profile
NB-3111 – Drug Profile
Novo-29 – Drug Profile
NP-108 – Drug Profile
NP-432 – Drug Profile
Nu-3 – Drug Profile
NVB-333 – Drug Profile
OG-253 – Drug Profile
OTP-602 – Drug Profile
P-100031 – Drug Profile
Panaecin – Drug Profile
PIND-146007 – Drug Profile
PK-150 – Drug Profile
Protein for Infectious Disease and Inflammation – Drug Profile
Qn-2705 – Drug Profile
RECCE-327 – Drug Profile
Recombinant Protein for Infectious Diseases – Drug Profile
Recombinant Protein for MRSA Infections – Drug Profile
Recombinant Proteins for Anthrax and Methicillin Resistant Staphylococcus Aureus (MRSA) Infections – Drug Profile
SAAP-148 – Drug Profile
SASPjectPT-1.2 – Drug Profile
SC-5005 – Drug Profile
SCA-50 – Drug Profile
SCB-203 – Drug Profile
SK-0392 – Drug Profile
SM-1S26 – Drug Profile
Small Molecule for Gram-Positive Bacterial Infections – Drug Profile
Small Molecule for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profile
Small Molecule for Methicillin-Resistant Staphylococcus aureus Infections – Drug Profile
Small Molecule to Inhibit crtN for Staphylococcus aureus Infections – Drug Profile
Small Molecule to Inhibit DNA Gyrase for Gram Positive Bacterial Infections – Drug Profile
Small Molecule to Inhibit FabI for MRSA Infection – Drug Profile
Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections – Drug Profile
Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections – Drug Profile
Small Molecule to Inhibit Wall Teichoic Acid for MRSA Infections – Drug Profile
Small Molecules for Bacterial Infections – Drug Profile
Small Molecules for Bacterial Infections and Bone Disorders – Drug Profile
Small Molecules for Gram Positive Bacterial Infections – Drug Profile
Small Molecules for Gram-Positive Bacterial Infections – Drug Profile
Small Molecules for Gram-Positive Bacterial Infections and MRSA Infections – Drug Profile
Small Molecules for Infectious Diseases – Drug Profile
Small Molecules for Methicillin Resistant Staphylococcus aureus Infections – Drug Profile
Small Molecules for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drug Profile
Small Molecules for MRSA and VRSA Infections – Drug Profile
Small Molecules for MRSA Infections – Drug Profile
Small Molecules for Staphylococcal Infections – Drug Profile
Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections – Drug Profile
Small Molecules to Inhibit Acyl Carrier Protein Synthase for Methicillin-Resistant Staphylococcus aureus Infections – Drug Profile
Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections – Drug Profile
Small Molecules to Inhibit Bacterial Cell Membrane for MRSA Infection – Drug Profile
Small Molecules to Inhibit bNOS for MRSA Infections – Drug Profile
Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections – Drug Profile
Small Molecules to Inhibit Fabl for Staphylococcal Aureus and MRSA Infections – Drug Profile
Small Molecules to Inhibit ftsz for Infectious Disease – Drug Profile
Small Molecules to Inhibit KasA for Gram-Positive and Gram-Negative Bacterial Infections – Drug Profile
Small Molecules to Inhibit Lipid II for Methicillin-Resistant Staphylococcus aureus Associated Skin Infections – Drug Profile
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections – Drug Profile
Small Molecules to Inhibit MenA for Bacterial Infections – Drug Profile
Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections – Drug Profile
Small Molecules to Inhibit MRAY for Methicillin-Resistant Staphylococcus aureus Infections – Drug Profile
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections – Drug Profile
Small Molecules to Inhibit Pyruvate Kinase for MRSA Infections – Drug Profile
Small Molecules to Inhibit Sortase A for Gram-Positive Bacterial Infections – Drug Profile
SNSP-113 – Drug Profile
SOM-001 – Drug Profile
Staphylococcus aureus (bivalent, virus like particle) vaccine – Drug Profile
Staphylococcus aureus (multivalent) vaccine – Drug Profile
Staphylococcus aureus vaccine – Drug Profile
STI-001 – Drug Profile
Synthetic Peptide to Disrupt Bacterial Cell Membrane for Bacterial Infections – Drug Profile
Synthetic Peptides for Gram Positive Bacterial Infections – Drug Profile
Synthetic Peptides for MRSA Infections – Drug Profile
Synthetic Peptides for Staphylococcus Aureus Infections and H1N1 Influenza – Drug Profile
Synthetic Peptides to Disrupt Bacterial Cell Membrane for MRSA and Escherichia coli Infections – Drug Profile
T-145 – Drug Profile
targocil – Drug Profile
Taro Inhibitor – Drug Profile
taromycin A – Drug Profile
teicoplanin – Drug Profile
Teixobactin – Drug Profile
TNM-012 – Drug Profile
TNS-18 – Drug Profile
Tolasure – Drug Profile
TP-0480066 – Drug Profile
TPH-101 – Drug Profile
TRL-1068 – Drug Profile
TS-2037 – Drug Profile
TXA-709 – Drug Profile
Vaccine for MRSA Infections – Drug Profile
VT-02 – Drug Profile
WCK-4086 – Drug Profile
WLBU-2 – Drug Profile
YSA-2021 – Drug Profile
YV-11455 – Drug Profile
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Product Development Milestones
Featured News & Press Releases
Jul 19, 2022: Destiny Pharma announces positive update from US FDA on XF-73 phase 3
Jul 08, 2022: Prokaryotics receives SBIR phase IIB award supporting preclinical candidate selection for ß-lactam potentiator program
May 26, 2022: Rationale for FDA’s position on oxacillin breakpoints for staphylococcus
Mar 31, 2022: Data on the antimicrobial activity of XF-73 against bacteria within biofilms to be presented at prestigious 2022 ECCMID Congress
Feb 08, 2022: Positive feedback from EMA on XF-73 Nasal gel phase 3 programme
Oct 12, 2021: Prokaryotics announces that two patents covering novel compounds which restore the efficacy of commonly used ß-lactams against MRSA have been issued by the U.S. Patent and Trademark Office
May 04, 2021: Botanix update on BTX 1801 clinical development
Mar 31, 2021: Aptorum Group announces dosing first human subject in a phase I clinical trial of ALS-4, a first-in-class small molecule drug designed to treat infections caused by Staphylococcus aureus including Methicillin-Resistant Staphylococcus aureus
Mar 29, 2021: Destiny Pharma reports positive phase 2b results for XF-73 Nasal Gel
Mar 18, 2021: Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis
Feb 19, 2021: Botanix attends 2nd Dermatology Drug Development Summit Europe
Jan 20, 2021: Aptorum Group receives clearance from health canada to initiate a phase 1 clinical trial for ALS-4, a small molecule drug for infections caused by staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Dec 21, 2020: Aptorum Group announces submission of clinical trial application for ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Sep 02, 2020: Dartmouth-led team engineers new treatment for drug-resistant bacterial infections
Sep 01, 2020: Aptorum Group announces further positive data on ALS-4 against MRSA wound infection and MRSA Bacteraemia against Linezolid and Vancomycin respectively in in vivo models
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
Table 8: Number of Products under Development by Universities/Institutes, 2022
Table 9: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
Table 10: Number of Products under Development by Universities/Institutes, 2022 (Contd..2)
Table 11: Products under Development by Companies, 2022
Table 12: Products under Development by Companies, 2022 (Contd..1)
Table 13: Products under Development by Companies, 2022 (Contd..2)
Table 14: Products under Development by Companies, 2022 (Contd..3)
Table 15: Products under Development by Companies, 2022 (Contd..4)
Table 16: Products under Development by Companies, 2022 (Contd..5)
Table 17: Products under Development by Companies, 2022 (Contd..6)
Table 18: Products under Development by Universities/Institutes, 2022
Table 19: Products under Development by Universities/Institutes, 2022 (Contd..1)
Table 20: Products under Development by Universities/Institutes, 2022 (Contd..2)
Table 21: Number of Products by Stage and Target, 2022
Table 22: Number of Products by Stage and Target, 2022 (Contd..1)
Table 23: Number of Products by Stage and Target, 2022 (Contd..2)
Table 24: Number of Products by Stage and Mechanism of Action, 2022
Table 25: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 26: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Table 27: Number of Products by Stage and Route of Administration, 2022
Table 28: Number of Products by Stage and Molecule Type, 2022
Table 29: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AbbVie Inc, 2022
Table 30: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Acticule Life Sciences Ltd, 2022
Table 31: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Acurx Pharmaceuticals Inc, 2022
Table 32: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AEON Medix Inc, 2022
Table 33: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AimMax Therapeutics Inc, 2022
Table 34: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AlphaMab Co Ltd, 2022
Table 35: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Amicrobe Inc, 2022
Table 36: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Amprologix Ltd, 2022
Table 37: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AnyGen Co Ltd, 2022
Table 38: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aphios Corp, 2022
Table 39: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aridis Pharmaceuticals Inc, 2022
Table 40: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Arietis Corp, 2022
Table 41: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aurigene Discovery Technologies Ltd, 2022
Table 42: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Basilea Pharmaceutica Ltd, 2022
Table 43: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bharat Biotech Ltd, 2022
Table 44: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Biomendics LLC, 2022
Table 45: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by BioPlx Microbiomics Pvt Ltd, 2022
Table 46: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bioseka UAB, 2022
Table 47: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bioversys AG, 2022
Table 48: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Botanix Pharmaceuticals Ltd, 2022
Table 49: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cantab Anti-infectives Ltd, 2022
Table 50: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cellics Therapeutics Inc, 2022
Table 51: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Centivax Inc, 2022
Table 52: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022
Table 53: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Crestone Inc, 2022
Table 54: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CrystalGenomics Inc, 2022
Table 55: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CSA Biotechnologies LLC, 2022
Table 56: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Curza Global LLC, 2022
Table 57: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Daiichi Sankyo Co Ltd, 2022
Table 58: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Debiopharm International SA, 2022
Table 59: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by DeNovaMed Inc, 2022
Table 60: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Destiny Pharma Plc, 2022
Table 61: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Eagle Pharmaceuticals Inc, 2022
Table 62: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Enesi Pharma Ltd, 2022
Table 63: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ESA Patentverwertungsagentur Sachsen-Anhalt GmbH, 2022
Table 64: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Exbaq LLC, 2022
Table 65: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Global BioLife Inc Ltd, 2022
Table 66: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Helperby Therapeutics Group Ltd, 2022
Table 67: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Histogen Inc, 2022
Table 68: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Hsiri Therapeutics LLC, 2022
Table 69: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by HyPharm GmbH, 2022
Table 70: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ImmunArtes LLC, 2022
Table 71: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Immupharma Plc, 2022
Table 72: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Inimmune Corp, 2022
Table 73: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Integrated BioTherapeutics Inc, 2022
Table 74: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ioGenetics Inc, 2022
Table 75: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Johnson & Johnson, 2022
Table 76: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by KBP Biosciences Co Ltd, 2022
Table 77: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lakewood-Amedex Inc, 2022
Table 78: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lead Discovery Center GmbH, 2022
Table 79: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by LegoChem Biosciences Inc, 2022
Table 80: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lysimmune BioScience, 2022
Table 81: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lyticon LLC, 2022
Table 82: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Madam Therapeutics BV, 2022
Table 83: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Matrisys Bioscience Inc, 2022
Table 84: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Meiji Seika Pharma Co Ltd, 2022
Table 85: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MGB Biopharma Ltd, 2022
Table 86: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Microbiotix Inc, 2022
Table 87: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MicuRx Pharmaceuticals Inc, 2022
Table 88: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Naicons Srl, 2022
Table 89: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Neupharma Srl, 2022
Table 90: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novabiotics Ltd, 2022
Table 91: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novalex Therapeutics Inc, 2022
Table 92: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovoBiotic Pharmaceuticals LLC, 2022
Table 93: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Olgram SAS, 2022
Table 94: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Opal Biosciences Ltd, 2022
Table 95: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oppilotech Ltd, 2022
Table 96: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oragenics Inc, 2022
Table 97: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oryn Therapeutics, 2022
Table 98: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oxford Drug Design Ltd, 2022
Table 99: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Peptineo, 2022
Table 100: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Pharma Holdings AS, 2022
Table 101: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Phico Therapeutics Ltd, 2022
Table 102: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Prokaryotics Inc, 2022
Table 103: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Prommune Inc, 2022
Table 104: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Q2 Pharma Ltd, 2022
Table 105: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by QureTech Bio AB, 2022
Table 106: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Recce Pharmaceuticals Ltd, 2022
Table 107: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sano Chemicals Inc, 2022
Table 108: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Scandion Oncology AS, 2022
Table 109: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by SciBac Inc, 2022
Table 110: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sentinella Pharmaceuticals Inc, 2022
Table 111: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Shanghai Shangyao Xinya Pharmaceutical Co Ltd, 2022
Table 112: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, 2022
Table 113: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sinsa Labs Inc, 2022
Table 114: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Skye Bioscience Inc, 2022
Table 115: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sorrento Therapeutics Inc, 2022
Table 116: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Synspira Therapeutics Inc, 2022
Table 117: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
Table 118: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Table 119: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TAXIS Pharmaceuticals Inc, 2022
Table 120: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TGV-Inhalonix Inc, 2022
Table 121: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
Table 122: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Theravance Biopharma Inc, 2022
Table 123: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Trellis Bioscience Inc, 2022
Table 124: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Venomyx Inc, 2022
Table 125: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Viosera Therapeutics, 2022
Table 126: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Vitas Pharma Research Pvt Ltd, 2022
Table 127: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by VLP Biotech Inc, 2022
Table 128: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Wockhardt Ltd, 2022
Table 129: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Yungjin Pharm Co Ltd, 2022
Table 130: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
Table 131: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Zydus Lifesciences Ltd, 2022
Table 132: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022
Table 133: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..1)
Table 134: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..2)
Table 135: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..3)
Table 136: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..4)
Table 137: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..5)
Table 138: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..6)
Table 139: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..7)
Table 140: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..8)
Table 141: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, 2022 (Contd..9)
Table 142: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings